Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Sotio Biotech Inc.
VM Oncology, LLC
Merck Sharp & Dohme LLC
Incyte Corporation
Case Comprehensive Cancer Center